Advantages of long-term therapy with «Cognex»® in Alzheimer's disease;Vorteile der langzeitbehandlung mit Cognex® bei der Alzheimer-Krankheit

Praxis

Volumn 86, Issue 35, 1997, Pages 1350-1354

  Gracon, S ^a   Smith, F ^a   Shokry, A ^a,b  

^a PFIZER INC   (United States)

^b Warner Lambert (Schweiz) AG   (Switzerland)

Author keywords

Alzheimer's disease; Cognex; Nursing home disection

Indexed keywords

PLACEBO; TACRINE;

ADULT; ALZHEIMER DISEASE; CONFERENCE PAPER; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; NURSING HOME; QUALITY OF LIFE;

ACTIVITIES OF DAILY LIVING; AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INSTITUTIONALIZATION; LONG-TERM CARE; MALE; MENTAL STATUS SCHEDULE; NOOTROPIC AGENTS; QUALITY OF LIFE; TACRINE;

EID: 0030811364     PISSN: 16618157     EISSN: 16618165     Source Type: Journal    
DOI: None     Document Type: Review

References (22)

1. Clark M., Gosnell M.: A slow death of the mind; devastating for victims and families. Alzheimer's is now being recognized as "the disease of the century". Newsweek 1984 Dec 3:56.
2. Heyman A., Wilkinson W. E., Hurwitz B. J., et al.: Early-onset Alzheimer's disease: Clinical predictors of institutionalization and death. Neurology 1987; 37: 980-984.
3. Jost B. C., Grossberg G. T.: The natural history of Alzheimer's disease: A brain bank study. J Am Geriatr Soc 1995; 43: 1248-1255.
4. Feldman H., Gracon S.: Alzheimer's disease: Symptomatic drugs under development. In: Gautheir S., ed. Clinical diagnosis and management of Alzheimer's disease. London: Martin Dunitz, 1996; 15: 239-259.
5. Folstein M. F., Folstein S. E., McHugh P. R.: Minimental state. J Psychiatr Res 1975; 12: 189-198.
6. Drachman D. A., O'Donnell B. F., Lew R. A. et al.: The prognosis in Alzheimer's disease, "How far" rather than "how fast" best predicts the course. Arch Neurol 1990; 47: 851-856.
7. Levy M. L., Cummings J. L., Fairbanks L. A. et al.: Longitudinal assessment of symptoms of depression, agitation, and psychosis in 181 patients with Alzheimer's disease. Am J Psychiatry 1996; 153: 1438-1443.
8. Welch H. G., Walsh J. S., Larson E. B.:The cost of institutional care in Alzheimer's disease: Nursing home and hospital use in a prospective cohort. J Am Geriatr Soc 1992; 40: 221-224.
9. Berg L. Miller J. P., Storandt M. et al.: Mild senile dementia of the Alzheimer type, 2: Longitudinal assessment. Ann Neurol 1988; 23: 477-484.
10. Brodaty H., McGilchrist C., Harris L. et al.: Time until institutionalization and death in patients with dementia. Role of caregiver training and risk factors. Arch Neurol 1993; 50: 643-650.
11. Source: US National Institutes of Health, National Institute on Aging.
12. Ernst R. L., Hay J. W.: The US economic and social costs of Alzheimer's disease revisited. Am J Public Health 1994; 84: 1261-1264.
13. Farlow M., Gracon S. I., Hershey L. A. et al.: A controlled trial of tacrine in Alzhemer's disease. JAMA 1992; 268: 2523-2529.
14. Knapp M, J., Knopman D. S., Solomon P. R. et al.: A 30-week randomized controlled trial of high-dose tacrine in patients with Alzheimer's disease. JAMA 1994; 271: 985-991.
15. Knopman D., Schneider I., Davis K. et al.: Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality. Neurology 1996; 47: 166-177.
16. McKhann G., Drachman D., Folstein M. et al.: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of department of health and human services task force on Alzheimer's disease. Neurology 1984; 34: 939-44.
17. Lawton M. P., Brody E. M.: Assessment of older people: Self-maintaining and instrumental activities of daily living. Gerontology 1969; 9: 179-86.
18. Reisberg B., Ferris S. H., De Leon M. J. et al.: The global deterioration scale for assessment of primary degenerative dementia. Am J psychiatry 1982; 139: 1136-9.
19. SAS/STAT User's Guide, Version 6, Fourth Edition, Volumes 1 and 2, Cary, North Carolina: SAS Institute, Inc. 1990.
20. Leber P.: Guidelines for the evaluation of antidementia drugs: Frist draft. November 8, 1990. US Food and Drug Administration, Division of Neuropharmacology.
21. CPMP Working Party on Efficacy of Medicinal Products: Antidementia Medicinal Products. Draft 5, November 1992, Brussels, Belgium.
22. Smith F., Talwalker S., Gracon., Srirama M.: The Use of Survival Analysis Techniques in Evaluating the Effect of Long-Term Tacrine (Cognex) Treatment on Nursing Home Placement and Mortality in Patients with Alzheimer's Disease. Journal of Biopharmaceutical Statistics 1996; 6: 396-409.